Objectives:？Hyperinsulinemia as well as prolonged and elevated estrogen exposure are
considered as risk factors for endometrial cancer (EC) development.Metformin, an anti-hyperglycemic and
insulin-sensitizing biguanide, displayed anti-proliferative effects in recent
studies. In the present study, the effects of long-term
exposure of endometrial cancer cells to low and moderate concentrations of
metformin on cell viability, proliferation, clonogenicity and migration were
investigated under different metabolic conditions. Study Design:EC cell lines HEC-1A and Ishikawa were cultured
under normo- (NG, 5.5
mM) or hyperglycemic (HG, 17.0 mM) conditions and treated with metformin (0.01 - 5.0 mM) in the presence ofβ-estradiol (E2) for 7 d. Results:
References
[1]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
Garg, K. and Soslow, R.A. (2014) Endometrial Carcinoma in Women Aged 40 Years and Younger. Archives of Pathology & Laboratory Medicine, 138, 335-342.
https://doi.org/10.5858/arpa.2012-0654-RA
[3]
Amant, F., Mirza, M.R., Koskas, M. and Creutzberg, C.L. (2018) Cancer of the Corpus Uteri. International Journal of Gynecology & Obstetrics, 143, 37-50.
https://doi.org/10.1002/ijgo.12612
[4]
O’Connor, K.A., Ferrell, R.J., Brindle, E., Shofer, J., Holman, D.J., Miller, R.C., et al. (2009) Total and Unopposed Estrogen Exposure across Stages of the Transition to Menopause. Cancer Epidemiology, Biomarkers & Prevention, 18, 828-836.
https://doi.org/10.1158/1055-9965.EPI-08-0996
[5]
Clarke, C.L. and Sutherland, R.L. (1990) Progestin Regulation of Cellular Proliferation. Endocrine Reviews, 11, 266-301. https://doi.org/10.1210/edrv-11-2-266
[6]
Liu, Z., Qi, S., Zhao, X., Li, M., Ding, S., Lu, J., et al. (2016) Metformin Inhibits 17β-Estradiol-Induced Epithelial-to-Mesenchymal Transition via βKlotho-Related ERK1/2 Signaling and AMPKα Signaling in Endometrial Adenocarcinoma Cells. Oncotarget, 7, 21315-12331. https://doi.org/10.18632/oncotarget.7040
[7]
Szablewski, L. (2014) Diabetes Mellitus: Influences on Cancer Risk. Diabetes/Metabolism Research and Reviews, 30, 543-553.
https://doi.org/10.1002/dmrr.2573
[8]
Friberg, E., Orsini, N., Mantzoros, C.S. and Wolk, A. (2007) Diabetes Mellitus and Risk of Endometrial Cancer: A Meta-Analysis. Diabetologia, 50, 1365-1374.
https://doi.org/10.1007/s00125-007-0681-5
[9]
Barone, B.B., Yeh, H.C., Snyder, C.F., Peairs, K.S., Stein, K.B., Derr, R.L., et al. (2008) Long-Term All-Cause Mortality in Cancer Patients with Preexisting Diabetes Mellitus: A Systematic Review and Meta-Analysis. JAMA, 300, 2754-2764.
https://doi.org/10.1001/jama.2008.824
[10]
Daugan, M., Dufay Wojcicki, A., d’Hayer, B. and Boudy, V. (2016) Metformin: An Anti-Diabetic Drug to Fight Cancer. Pharmacological Research, 113, 675-685.
https://doi.org/10.1016/j.phrs.2016.10.006
[11]
Dowling, R.J., Niraula, S., Stambolic, V. and Goodwin, P.J. (2012) Metformin in Cancer: Translational Challenges. Journal of Molecular Endocrinology, 48, R31-R43.
https://doi.org/10.1530/JME-12-0007
[12]
Umene, K., Banno, K., Kisu, I., Yanokura, M., Nogami, Y., Tsuji, K., et al. (2013) New Candidate Therapeutic Agents for Endometrial Cancer: Potential for Clinical Practice. Oncology Reports, 29, 855-860. https://doi.org/10.3892/or.2013.2221
[13]
Febbraro, T., Lengyel, E. and Romero, I.L. (2014) Old Drug, New Trick: Repurposing Metformin for Gynecologic Cancers? Gynecologic Oncology, 135, 614-621.
https://doi.org/10.1016/j.ygyno.2014.10.011
[14]
He, H., Ke, R., Lin, H., Ying, Y., Liu, D. and Luo, Z. (2015) Metformin, an Old Drug, Brings a New Era to Cancer Therapy. The Cancer Journal, 21, 70-74.
https://doi.org/10.1097/PPO.0000000000000103
[15]
Samuel, V.P., Dahiya, R., Singh, Y., Gupta, G., Sah, S.K., Gubbiyappa, S.K., et al. (2019) Metformin: A Salutary Candidate for Colorectal Cancer Treatment in Patients with Diabetes. Journal of Environmental Pathology, Toxicology and Oncology, 38, 133-141. https://doi.org/10.1615/JEnvironPatholToxicolOncol.2019029388
[16]
Abdel-Wahab, A.F., Mahmoud, W. and Al-Harizy, R.M. (2019) Targeting Glucose Metabolism to Suppress Cancer Progression: Prospective of Anti-Glycolytic Cancer Therapy. Pharmacological Research, 150, Article ID: 104511.
https://doi.org/10.1016/j.phrs.2019.104511
[17]
Coperchini, F., Leporati, P., Rotondi, M. and Chiovato, L. (2015) Expanding the Therapeutic Spectrum of Metformin: From Diabetes to Cancer. Journal of Endocrinological Investigation, 38, 1047-1055.
https://doi.org/10.1007/s40618-015-0370-z
[18]
Wallbillich, J.J., Josyula, S., Saini, U., Zingarelli, R.A., Dorayappan, K.D., Riley, M.K., et al. (2017) High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer. PLoS ONE, 12, e0170318. https://doi.org/10.1371/journal.pone.0170318
[19]
Wu, B., Li, S., Sheng, L., Zhu, J., Gu, L., Shen, H., et al. (2012) Metformin Inhibits the Development and Metastasis of Ovarian Cancer. Oncology Reports, 28, 903-908.
https://doi.org/10.3892/or.2012.1890
[20]
Machado Weber, A., Strowitzki, T. and Germeyer, A. (2018) High Glucose Levels Interferes the Endometrial Cancer Cell Response to Metformin Treatment over Time. British Journal of Research, 5, Article No. 44.
https://doi.org/10.21767/2394-3718.100044
[21]
de Barros Machado, A., Dos Reis, V., Weber, S., Jauckus, J., Brum, I.S., von Eye Corleta, H., et al. (2016) Proliferation and Metastatic Potential of Endometrial Cancer Cells in Response to Metformin Treatment in a High versus Normal Glucose Environment. Oncology Letters, 12, 3626-3632.
https://doi.org/10.3892/ol.2016.5041
[22]
Shao, R., Li, X., Feng, Y., Lin, J.F. and Billig, H. (2014) Direct Effects of Metformin in the Endometrium: A Hypothetical Mechanism for the Treatment of Women with PCOS and Endometrial Carcinoma. Journal of Experimental & Clinical Cancer Research, 33, Article No. 41. https://doi.org/10.1186/1756-9966-33-41
[23]
Feoktistova, M., Geserick, P. and Leverkus, M. (2016) Crystal Violet Assay for Determining Viability of Cultured Cells. Cold Spring Harbor Protocols, 2016, 343-346.
https://doi.org/10.1101/pdb.prot087379
[24]
Schneider, C.A., Rasband, W.S. and Eliceiri, K.W. (2012) NIH Image to ImageJ: 25 Years of Image Analysis. Nature Methods, 9, 671-675.
https://doi.org/10.1038/nmeth.2089
[25]
Guzmán, C., Bagga, M., Kaur, A., Westermarck, J. and Abankwa, D. (2014) ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays. PLoS ONE, 9, e92444. https://doi.org/10.1371/journal.pone.0092444
[26]
Grada, A., Otero-Vinas, M., Prieto-Castrillo, F., Obagi, Z. and Falanga, V. (2017) Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. Journal of Investigative Dermatology, 137, e11-e16.
https://doi.org/10.1016/j.jid.2016.11.020
[27]
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F., Pellegrini, F. and Nicolucci, A. (2013) Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review. PLoS ONE, 8, e71583.
https://doi.org/10.1371/journal.pone.0071583
[28]
Mitsuhashi, A., Kiyokawa, T., Sato, Y. and Shozu, M. (2014) Effects of Metformin on Endometrial Cancer Cell Growth in Vivo: A Preoperative Prospective Trial. Cancer, 120, 2986-2995. https://doi.org/10.1002/cncr.28853
[29]
Qu, W., Zhao, Y., Wang, X., Qi, Y., Zhou, C., Hua, Y. et al. (2019) Culture Characters, Genetic Background, Estrogen/Progesterone Receptor Expression, and Tumorigenic Activities of Frequently Used Sixteen Endometrial Cancer Cell Lines. Clinica Chimica Acta, 489, 225-232. https://doi.org/10.1016/j.cca.2018.08.013
[30]
Hevir-Kene, N. and Rizner, T.L. (2015) The Endometrial Cancer Cell Lines Ishikawa and HEC-1A, and the Control Cell Line HIEEC, Differ in Expression of Estrogen Biosynthetic and Metabolic Genes, and in Androstenedione and Estrone-Sulfate Metabolism. Chemico-Biological Interactions, 234, 309-319.
https://doi.org/10.1016/j.cbi.2014.11.015
[31]
Filigheddu, N., Sampietro, S., Chianale, F., Porporato, P.E., Gaggianesi, M., Gregnanin, I., et al. (2011) Diacylglycerol Kinase α Mediates 17-β-Estradiol-Induced Proliferation, Motility, and Anchorage-Independent Growth of Hec-1A Endometrial Cancer Cell Line through the G Protein-Coupled Estrogen Receptor GPR30. Cellular Signalling, 23, 1988-1996. https://doi.org/10.1016/j.cellsig.2011.07.009
[32]
Lu, J., Zhang, X., Zhang, R. and Ge, Q. (2015) MicroRNA Heterogeneity in Endometrial Cancer Cell Lines Revealed by Deep Sequencing. Oncology Letters, 10, 3457-3465. https://doi.org/10.3892/ol.2015.3776
[33]
Wise, M.R., Jordan, V., Lagas, A., Showell, M., Wong, N., Lensen, S., et al. (2016) Obesity and Endometrial Hyperplasia and Cancer in Premenopausal Women: A Systematic Review. American Journal of Obstetrics & Gynecology, 214, 689E.1-689E.17.
https://doi.org/10.1016/j.ajog.2016.01.175
[34]
Ryu, T.Y., Park, J. and Scherer, P.E. (2014) Hyperglycemia as a Risk factor for Cancer Progression. Diabetes & Metabolism Journal, 38, 330-336.
https://doi.org/10.4093/dmj.2014.38.5.330
[35]
Berger, N.A. (2014) Obesity and Cancer Pathogenesis. Annals of the New York Academy of Sciences, 1311, 57-76. https://doi.org/10.1111/nyas.12416
[36]
Cantrell, L.A., Zhou, C., Mendivil, A., Malloy, K.M., Gehrig, P.A. and Bae-Jump, V.L. (2010) Metformin Is a Potent Inhibitor of Endometrial Cancer Cell Proliferation—Implications for a Novel Treatment Strategy. Gynecologic Oncology, 116, 92-98. https://doi.org/10.1016/j.ygyno.2009.09.024
[37]
Takahashi, A., Kimura, F., Yamanaka, A., Takebayashi, A., Kita, N., Takahashi, K., et al. (2014) Metformin Impairs Growth of Endometrial Cancer Cells via Cell Cycle Arrest and Concomitant Autophagy and Apoptosis. Cancer Cell International, 14, Article No. 53. https://doi.org/10.1186/1475-2867-14-53
[38]
Luo, J., Beresford, S., Chen, C., Chlebowski, R., Garcia, L., Kuller, L., et al. (2014) Association between Diabetes, Diabetes Treatment and Risk of Developing Endometrial Cancer. British Journal of Cancer, 111, 1432-1439.
https://doi.org/10.1038/bjc.2014.407
[39]
Clement, N.S., Oliver, T.R., Shiwani, H., Sanner, J.R., Mulvaney, C.A. and Atiomo, W. (2017) Metformin for Endometrial Hyperplasia. Cochrane Database of Systematic Reviews, No, 10, Article No. CD012214.
https://doi.org/10.1002/14651858.CD012214.pub2
